Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACHIM
- Development stage
- Unknown
- Lead developer
- Oslo University Hospital
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intraintestinal
01
Overview
ACHIM (Anaerobic Cultivated Human Intestinal Microbiome) is a standardized, single-donor live biotherapeutic product consisting of cultivated intestinal bacteria derived from human microbiota. Developed and investigated by Oslo University Hospital, it is intended to treat gastrointestinal symptoms, such as bloating and diarrhea, in patients with systemic sclerosis (SSc). The product is administered via endoscopic infusion (gastroduodenoscopy) into the small intestine. Its mechanism of action involves the restoration or modification of the patient's gut microbiome composition to alleviate dysbiosis-related symptoms and possibly influence immune networks. In the Phase 2 ReSScue trial, ACHIM was found to be well-tolerated but did not demonstrate a statistically significant improvement in lower gastrointestinal symptoms compared to placebo.
- Other names
- Anaerobic Cultivated Human Intestinal MicrobiomeACHIM-Oslo University Hospital-systemic sclerosis
Beyond the preview
Go deeper on ACHIM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACHIM.